Physician profile
Ashish Agarwal
NPI 1821174483
$1,387.09
in general payments reported to CMS, 2019-2025
17 companies · $56.92 in 2025
The $56.92 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $107 · 2021: $119 · 2022: $368 · 2023: $151 · 2024: $170 · 2025: $56.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $236.06 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $212.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $167.50 | 2019-2022 | |
| Boston Scientific Corporation | $134.56 | 2023 | Watchman Flx, Watchman Access System |
| Medtronic, INC. | $123.37 | 2024 | Endoflip |
| Amgen INC. | $120.54 | 2019-2025 | Repatha, Repatha |
| Regeneron Healthcare Solutions, INC. | $71.64 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $44.87 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $44.50 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $43.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.66 | 2019 | |
| Merck Sharp & Dohme LLC | $35.99 | 2022 | |
| Amarin Pharma, INC. | $29.92 | 2019 | |
| Gilead Sciences, INC. | $28.99 | 2019 | |
| Pfizer INC. | $26.83 | 2020-2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $15.60 | 2024 | Paradise Renal Denervation System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.